Bulletin of Experimental Biology and Medicine

, Volume 129, Issue 4, pp 359–361

Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration

  • S. S. Boiko
  • R. U. Ostrovskaya
  • V. P. Zherdev
  • S. A. Korotkov
  • T. A. Gudasheva
  • T. A. Voronina
  • S. B. Seredenin
Pharmacology and Toxicology

DOI: 10.1007/BF02439270

Cite this article as:
Boiko, S.S., Ostrovskaya, R.U., Zherdev, V.P. et al. Bull Exp Biol Med (2000) 129: 359. doi:10.1007/BF02439270

Abstract

Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an umodified state.

Key words

acylprolyldipeptide GVS-111 pharmacokinetics blood-brain barrier permeability 

Copyright information

© Kluwer Academic/Plenum Publishers 2000

Authors and Affiliations

  • S. S. Boiko
    • 1
  • R. U. Ostrovskaya
    • 1
  • V. P. Zherdev
    • 1
  • S. A. Korotkov
    • 1
  • T. A. Gudasheva
    • 1
  • T. A. Voronina
    • 1
  • S. B. Seredenin
    • 1
  1. 1.Laboratory of PharmacokineticsInstitute of Pharmacology, Russian Academy of Medical SciencesMoscow